Quick Answer
AIM ImmunoTech Inc. reported Net Income Loss of -$13.96 million for the year ending 2025.
- AIM ImmunoTech Inc. showed an increase of +19.4% in Net Income Loss from 2024 to 2025.
- This data is from AIM ImmunoTech Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), AIM ImmunoTech Inc.'s Net Income Loss has grown by 14.0%.
- Historical annual values: Fiscal year 2025: -$13.96 million | Fiscal year 2024: -$17.32 million | Fiscal year 2023: -$28.96 million | Fiscal year 2022: -$19.45 million | Fiscal year 2021: -$19.13 million | Fiscal year 2020: -$14.40 million | Fiscal year 2019: -$9.40 million | Fiscal year 2018: -$9.83 million | Fiscal year 2017: -$8.26 million | Fiscal year 2016: -$7.50 million | Fiscal year 2015: -$15.23 million | Fiscal year 2014: -$17.45 million | Fiscal year 2013: -$16.23 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: